<DOC>
	<DOCNO>NCT00669695</DOCNO>
	<brief_summary>The aim clinical trial evaluate effect Atorvastatin endothelial function improvement obstructive sleep apnea syndrome ( OSAS ) 3 month treatment , double-blind , randomize , placebo-controlled , multi-center study . An interim analysis perform 25 patient per group include .</brief_summary>
	<brief_title>Systemic Inflammation Obstructive Sleep Apnea Syndrome : Effect Atorvastatin</brief_title>
	<detailed_description>Secondary objective clinical trial : - To evaluate effect Atorvastatin comparison placebo inflammation occur OSAS , 3 month treatment . - To evaluate effect Atorvastatin comparison placebo insulin-resistance associate OSAS , 3 month treatment . - To evaluate effect Atorvastatin comparison placebo hypercholesterolemia associate OSAS , 3 month treatment . - To evaluate 6 month , effect continuous positive airway pressure ( CPAP ) + Atorvastatin association previously cite parameter , comparison Atorvastatin , CPAP placebo . - To measure CPAP efficiency comparison sham CPAP patient receive placebo , 3 month treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Men woman &gt; 18 year old Subjects diagnose OSAS ( apnea/hypopnea index = AHI &gt; 30/h ) Subjects clinical ATH grade I II control monotherapy ( 140 &lt; SAP &lt; 180 mmHg 90 &lt; DAP &lt; 110 mmHg ) Patients history prior stroke coronary ischemic disease Chronic respiratory disease ( PaO2 &lt; 60 mmHg and/or PaCO2 &gt; 45 mmHg ) Lung disease Hypothyroidism Statin treatment Antihypertensive treatment one drug Pregnant lactate woman Alcohol consumption &gt; 3 units/day Treatment itraconazole , ketoconazole , antiprotease , fibrates , antivitamin K , diltiazem , verapamil , erythromycin , clarithromycin , cyclosporin . Hypersensitivity one drug compound Patients modify concomitant treatment 3 month inclusion Potentially dangerous sleepiness Jobs risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>statin</keyword>
	<keyword>cardiovascular risk</keyword>
	<keyword>Obstructive sleep apnea syndrome ( OSAS ) patient</keyword>
</DOC>